The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

Roscovitine (ID 23)

Lecture Time
11:35 - 12:00
Speakers
  • Laurent Meijer (Roscoff, FR)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Preclinical evidence of efficacy (ID 5) Educational session

Preclinical evidence of activity of abemaciclib (ID 14)

Lecture Time
17:20 - 17:40
Speakers
  • Maria Lallena (Alcobendas, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

The biology of the CDK4–CDK6–RB pathway (ID 5)

Lecture Time
13:40 - 14:00
Speakers
  • Tobias Otto (Aachen, DE)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Ribociclib (ID 29)

Lecture Time
13:50 - 14:10
Speakers
  • Fabrice André (Villejuif, FR)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

PIK3 (ID 19)

Lecture Time
09:40 - 10:00
Speakers
  • Violeta Serra (Barcelona, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

DNA damage and checkpoint kinases (ID 10)

Lecture Time
15:30 - 15:50
Speakers
  • Fabrizio D'Adda di Fagagna (Milan, IT)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
Welcome and introduction (ID 1) Educational session

Welcome to the Symposium (ID 34)

Lecture Time
11:30 - 11:45
Speakers
  • Alberto Bardelli (Candiolo, IT)
  • Josep Tabernero (Barcelona, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
11:30 - 11:45
The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

Dinaciclib (ID 24)

Lecture Time
11:10 - 11:35
Speakers
  • Cristina Saura (Barcelona, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Preclinical evidence of efficacy (ID 5) Educational session

Comparison of preclinical data across CDK 4-6 (ID 15)

Lecture Time
17:40 - 18:00
Speakers
  • Romano Danesi (Pisa, IT)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

Q&A (ID 6)

Lecture Time
14:00 - 14:10
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Abemaciclib (ID 30)

Lecture Time
14:10 - 14:30
Speakers
  • Antonio Llombart-Cussac (Valencia, ES)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

MEK (ID 20)

Lecture Time
10:00 - 10:20
Speakers
  • Olivier Michielin (Lausanne, CH)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50